Real outcomes across life sciences compliance and enterprise IT — from GxP data integrity and real-time release to cloud modernization and Zero-Trust security.
Pre-inspection audits exposed critical data-integrity vulnerabilities across stand-alone HPLC and GC workstations: shared local admin accounts, unencrypted raw audit trails, and no automated review triggers — risking FDA 483s or OAI status under 21 CFR Part 11 and EU GMP Annex 11.
Variable tablet dissolution and intermittent blend-uniformity failures drove off-spec rejections and long OOS/CAPA investigations. In-process control relied on intrusive thief sampling and offline Karl Fischer moisture testing — up to 8 hours per run, with sampling bias.
A multi-regional supply-chain platform ran on a monolithic backend with API latency over 1.2s under load, caused by coupled SQL databases, plus production downtime during every bi-weekly release.
Permanent hybrid work expanded the attack surface across unmanaged laptops, while a legacy site-to-site VPN created bottlenecks and allowed lateral movement and data-leak risk.
Tell us about your compliance or technology challenge — we’ll show you how we can help.